Genitourinary Cancer
Conference Coverage
Atezolizumab plus chemo gives slight PFS edge in mUC
BARCELONA – Adding the immune checkpoint inhibitor atezolizumab to platinum-based chemotherapy offered a modest PFS benefit over chemotherapy...
From the Journals
Cancer burden: Multiple metrics needed to clarify the big picture
A cancer’s so-called epidemiologic signature – the composite pattern of incidence, mortality, and metastatic incidence – helps sort out the...
From the Journals
No difference between ipilimumab/nivolumab combo and immunotherapy plus VEGF for metastatic RCC
Therefore, the treatment should probably be directed by patient preferences, among other things, the investigators said.
Conference Coverage
PARP inhibitor prolongs PFS in mCRPC
BARCELONA – The PROfound trial shows that targeted therapy can be effective against metastatic castration-resistant prostate cancer bearing DNA...
Conference Coverage
Adjuvant radiotherapy no better than salvage post prostatectomy
BARCELONA – Men who underwent prostatectomy fared just as well with observation and salvage radiotherapy as with adjuvant radiotherapy.
Conference Coverage
Hormone therapy may do more harm than good for men with low PSA before early salvage radiation
Adding an antiandrogen may increase the risk of other-cause mortality by twofold or more for men with prostate cancer who have a low PSA level...
Conference Coverage
SABR may put immunological brakes on oligometastatic prostate cancer
In a randomized trial of 54 patients with oligometastatic prostate cancer, 61% of patients in the observation group had experienced disease...
From the Journals
PBRM1 mutations not quite up to snuff as ccRCC biomarkers
Truncating mutations in PBRM1 are moderately linked to response to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma.
From the Journals
SABR offers surgery alternative for localized RCC
Patients with smaller tumors had the best outcomes.
News
FDA approves darolutamide for nonmetastatic CRPC
The approval was based on improved metastasis free survival in the randomized ARAMIS trial of 1,509 patients with nonmetastatic, castration-...
From the Journals
Erdafitinib is efficacious in FGFR-altered urothelial carcinoma
The drug had good antitumor activity in the pretreated trial population, despite high rates of grade 3 or worse treatment-related adverse events...